Hologic, Inc. (HOLX) Q2 2025 Earnings Call Transcript
Hologic, Inc. (NASDAQ:HOLX ) Q2 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Mike Watts - Corporate VP, IR Steve MacMillan - Chairman, President & CEO Essex Mitchell - COO Karleen Oberton - CFO Conference Call Participants Patrick Donnelly - Citi Tejas Savant - Morgan Stanley Jack Meehan - Nephron Research Puneet Souda - Leerink Partners Anthony Petrone - Mizuho Group Lu Li - UBS Casey Woodring - JP Morgan Conor McNamara - RBC Capital Andrew Cooper - Raymond James Mason Carrico - Stephens Operator Good afternoon, and welcome to Hologic's Second Quarter Fiscal 2025 Earnings Conference Call. My name is Rachel, and I'm your operator for today's call.
Hologic (HOLX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Hologic (HOLX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Hologic (HOLX) Tops Q2 Earnings and Revenue Estimates
Hologic (HOLX) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $1.03 per share a year ago.
Insights Into Hologic (HOLX) Q2: Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Hologic (HOLX) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
GYN Surgical Division Likely to Drive Hologic's Q2 Earnings
HOLX's second-quarter fiscal 2025 performance is likely to have benefited from expanding breast health offerings.
Hologic Set to Report Q2 Earnings: Buy, Sell or Hold the Stock?
Molecular Diagnostics is likely to have aided HOLX's performance in the second quarter of fiscal 2025.
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside?
In recent times, investors have been increasingly drawn to companies operating in the molecular diagnostics space, a rapidly growing segment within the broader in-vitro diagnostics (IVD) market. According to Roots Analysis, the IVD market is projected to witness a 6.2% compound annual growth rate through 2035.
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hologic (HOLX) Advances While Market Declines: Some Information for Investors
Hologic (HOLX) concluded the recent trading session at $61.27, signifying a +0.67% move from its prior day's close.
Hologic Brings in New Leadership: A Signal to Stay Put With the Stock?
HOLX's diagnostics strength, robust international potential and new board addition support its "Hold" case. Yet, ongoing global uncertainties remain a drag.
Hologic (HOLX) Outperforms Broader Market: What You Need to Know
Hologic (HOLX) reachead $61.77 at the closing of the latest trading day, reflecting a +0.73% change compared to its last close.
